A Nigerian retrospective cohort study assessed whether dolutegravir-based antiretroviral therapy yields comparable birth outcomes to protease inhibitor–based regimens among 420 HIV-positive pregnant women. Investigators found no significant differences in adverse birth outcomes between the arms, while unsuppressed viral load emerged as the strongest predictor of risk. The findings reinforce the clinical importance of achieving viral suppression during pregnancy, a factor that can drive both maternal health and neonatal risk regardless of regimen class. For global PMTCT programs, the data contribute to evidence supporting regimen selection strategies built around virologic control, particularly in settings where access and monitoring capacity vary.
Get the Daily Brief